ENLV logo

Enlivex Therapeutics (ENLV) Cash And Cash Equivalents

Annual Cash & Cash Equivalents

$813.00 K
-$49.13 M-98.37%

December 31, 2023


Summary


Performance

ENLV Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherENLVbalance sheetmetrics:

Quarterly Cash And Cash Equivalents

$2.77 M
-$975.00 K-26.02%

September 30, 2024


Summary


Performance

ENLV Quarterly Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherENLVbalance sheetmetrics:

Cash And Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

ENLV Cash And Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-98.4%+40.6%
3 y3 years-85.7%-78.9%
5 y5 years-91.7%-78.9%

ENLV Cash And Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-98.4%at low-95.9%+241.0%
5 y5-year-98.4%at low-95.9%+241.0%
alltimeall time-98.4%+456.9%-95.9%+926.7%

Enlivex Therapeutics Cash And Cash Equivalents History

DateAnnualQuarterly
Sep 2024
-
$2.77 M(-26.0%)
Jun 2024
-
$3.75 M(+95.9%)
Mar 2024
-
$1.91 M(+135.3%)
Dec 2023
$813.00 K(-98.4%)
$813.00 K(-58.8%)
Sep 2023
-
$1.97 M(-43.0%)
Jun 2023
-
$3.46 M(-73.7%)
Mar 2023
-
$13.14 M(-73.7%)
Dec 2022
$49.95 M(+345.9%)
$49.95 M(+29.6%)
Sep 2022
-
$38.55 M(+91.3%)
Jun 2022
-
$20.15 M(-70.2%)
Mar 2022
-
$67.67 M(+504.1%)
Dec 2021
$11.20 M(+97.5%)
$11.20 M(-49.4%)
Sep 2021
-
$22.15 M(+75.6%)
Jun 2021
-
$12.61 M(+208.4%)
Mar 2021
-
$4.09 M(-27.9%)
Dec 2020
$5.67 M(+43.7%)
$5.67 M(+36.8%)
Sep 2020
-
$4.15 M(-59.2%)
Jun 2020
-
$10.16 M(-55.2%)
Mar 2020
-
$22.67 M(+474.1%)
Dec 2019
$3.95 M
$3.95 M(-27.5%)
Sep 2019
-
$5.45 M(-62.6%)
DateAnnualQuarterly
Jun 2019
-
$14.55 M(+6.6%)
Mar 2019
-
$13.64 M(+40.1%)
Dec 2018
$9.74 M(+176.1%)
$9.74 M(+481.6%)
Jun 2018
-
$1.67 M(-52.5%)
Dec 2017
$3.53 M(-48.7%)
$3.53 M(-14.1%)
Sep 2017
-
$4.11 M(-20.5%)
Jun 2017
-
$5.16 M(+25.9%)
Mar 2017
-
$4.10 M(-40.3%)
Dec 2016
$6.87 M(-5.7%)
$6.87 M(+16.0%)
Sep 2016
-
$5.92 M(-32.0%)
Jun 2016
-
$8.71 M(-8.5%)
Mar 2016
-
$9.53 M(+30.7%)
Dec 2015
$7.29 M(-31.2%)
$7.29 M(+47.3%)
Sep 2015
-
$4.95 M(-45.8%)
Jun 2015
-
$9.12 M(+30.1%)
Mar 2015
-
$7.01 M(-33.8%)
Dec 2014
$10.58 M(+3819.6%)
$10.58 M(-69.0%)
Sep 2014
-
$34.13 M(+704.3%)
Jun 2014
-
$4.24 M(+1471.5%)
Dec 2013
$270.00 K(+84.9%)
$270.00 K
Dec 2012
$146.00 K
-

FAQ

  • What is Enlivex Therapeutics annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Enlivex Therapeutics?
  • What is Enlivex Therapeutics annual cash & cash equivalents year-on-year change?
  • What is Enlivex Therapeutics quarterly cash and cash equivalents?
  • What is the all time high quarterly cash and cash equivalents for Enlivex Therapeutics?
  • What is Enlivex Therapeutics quarterly cash and cash equivalents year-on-year change?

What is Enlivex Therapeutics annual cash & cash equivalents?

The current annual cash & cash equivalents of ENLV is $813.00 K

What is the all time high annual cash & cash equivalents for Enlivex Therapeutics?

Enlivex Therapeutics all-time high annual cash & cash equivalents is $49.95 M

What is Enlivex Therapeutics annual cash & cash equivalents year-on-year change?

Over the past year, ENLV annual cash & cash equivalents has changed by -$49.13 M (-98.37%)

What is Enlivex Therapeutics quarterly cash and cash equivalents?

The current quarterly cash and cash equivalents of ENLV is $2.77 M

What is the all time high quarterly cash and cash equivalents for Enlivex Therapeutics?

Enlivex Therapeutics all-time high quarterly cash and cash equivalents is $67.67 M

What is Enlivex Therapeutics quarterly cash and cash equivalents year-on-year change?

Over the past year, ENLV quarterly cash and cash equivalents has changed by +$801.00 K (+40.64%)